Key Performance Highlights for the First Half of the Year
WuXi AppTec delivered impressive results in the first half of the year, with its profits exceeding 10 billion yuan for the first time. All three core businesses—Chemistry, Testing, and Biology—achieved double-digit growth, with the Chemistry business contributing the most. Due to its own laboratory monkey resources, the company has seen a significant increase in revenue from its drug safety evaluation services, especially amid the high demand for new drugs and the scarcity of these monkeys. With a substantial backlog of orders and an upward revision of its revenue forecast for 2026, WuXi AppTec demonstrates confidence in future growth. Additionally, a hearing has been held regarding the lawsuit filed by the U.S. Department of Defense, which has listed the company as a “Chinese military enterprise,” with the outcome still to be determined.
I. Profit Exceeds 10 Billion Yuan in the First Half; Adjusted Profit Growth Surpasses 80%
WuXi AppTec’s revenue for the first half of the year was 28.897 billion yuan, a year-on-year increase of 38.9%. The net profit attributable to the parent company reached 11.08 billion yuan, also exceeding 10 billion yuan for the first time, with a year-on-year growth of 29.43%. More noteworthy is the “adjusted non-IFRS net profit attributable to the parent company” (which represents the actual operating profit after excluding one-time gains and losses and special expenses), which amounted to 11.57 billion yuan, a significant increase of 83.2%, and the net profit margin rose to 40%. This indicates that the company’s daily operations are generating more revenue than its reported profits suggest, indicating an improvement in operational efficiency.
II. Double-Digit Growth Across All Three Core Businesses, with Chemistry as the Pillar
All three core businesses experienced double-digit growth:
1. Chemistry Business (the largest source of revenue): Revenue was 24.99 billion yuan, a year-on-year increase of 53.3%. This is due to customers advancing their drug development projects to later stages (such as clinical trials), resulting in higher fees, as well as the gradual deployment of new production capacity added last year, which enabled the company to take on more orders.
2. Testing Business (the second-largest source of revenue): Revenue was 2.48 billion yuan, a year-on-year increase of 31.5%. The drug safety evaluation business saw the fastest growth (42.8%), which is directly related to the company’s advantage in using laboratory monkeys.
3. Biology Business (the third-largest source of revenue): Revenue was 1.39 billion yuan, a year-on-year increase of 11.2%, although the growth rate was slower, it remained stable.
III. Scarcity of Laboratory Monkeys: WuXi AppTec Has a Competitive Edge
The development of new drugs such as multi-antibodies, ADCs, and small nucleic acids is currently very active, and these drugs require safety tests using laboratory monkeys in the pre-clinical phase. However, the supply of laboratory monkeys is limited, and prices have risen significantly. With its own monkey breeding facilities, WuXi AppTec has a better advantage in securing orders for safety evaluations. Customers can proceed with their projects more quickly without waiting for monkeys, which is why the growth rate of its safety evaluation business was even higher than in the first quarter.
IV. Abundant Orders and Upward Revision of Revenue Forecast for 2026
As of the end of June, WuXi AppTec had 66.43 billion yuan in unfinished orders, a year-on-year increase of 25.2%, indicating a secure source of revenue for the coming period. The company has also raised its revenue forecast for 2026 from 51.3-53 billion yuan to 58.5-60.5 billion yuan, with the growth rate increasing from 18%-22% to 35%-39%. This reflects the company’s confidence in future business growth and its expectation of securing more orders.
V. Lawsuit Related to the U.S. Department of Defense: Hearing Held, Outcome Pending
In June, WuXi AppTec was included in the U.S. Department of Defense’s list of “Chinese military enterprises,” which could impact its operations in the United States. The company filed a lawsuit to have itself removed from the list, and a hearing was held on July 22. As of August 3, no decision has been made. This situation poses a potential risk; if WuXi AppTec is not removed from the list, it may affect its business in the U.S. However, the outcome remains uncertain, and the company can only wait for the ruling.
Overall, WuXi AppTec’s performance in the first half of the year was strong, with steady growth across its core businesses. Its laboratory monkey resources are a unique advantage, and the future prospects look promising. However, the lawsuit from the U.S. Department of Defense is a factor that requires attention. For investors or those interested in the pharmaceutical industry, this information provides insights into the company’s operational status and potential future developments.